Latest Phase III trial data investigating Cabometyx in combination with immunotherapy to be presented at ASCO GU 2024

22.01.2024 - Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx and atezolizumab in metastatic castration-resistant prostate cancer Four-year extended ... Seite 1

Related Keywords

Paris ,France General ,France , ,Translational Research Unit At Georges Pompidou Hospital ,Oncology Clinical ,Translational Research Unit ,Georges Pompidou Hospital ,Ipsen Chart ,Psen Kurs ,Psen Aktie ,